1. Patient's cancer has a known primary driver alteration other than RET. For example, NSCLC with a targetable mutation in EGFR, ALK, ROS1 or BRAF; colorectal with an oncogenic KRAS, NRAS, or BRAF mutation.

2. Patient has any of the following within 14 days prior to the first dose of study drug:

3. Platelet count < 75 × 10^9/L.

4. Absolute neutrophil count <1.0 × 10^9/L.

5. Hemoglobin < 9.0 g/dL (red blood cell transfusion and erythropoietin may be used to reach at least 9.0 g/dL, but must have been administered at least 2 weeks prior to the first dose of study drug.

6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 × the upper limit of normal (ULN) if no hepatic metastases are present; >5 × ULN if hepatic metastases are present.

7. Total bilirubin > 1.5 × ULN; > 3 × ULN with direct bilirubin > 1.5 × ULN in presence of Gilbert's disease.

8. Estimated (Cockcroft-Gault formula) or measured creatinine clearance <40 mL/min.

9. Total serum phosphorus >5.5 mg/dL

10. QT interval corrected using Fridericia's formula (QTcF) >470 msec or history of prolonged QT syndrome or Torsades de pointes, or familial history of prolonged QT syndrome.

11. Clinically significant, uncontrolled, cardiovascular disease.

12. Central nervous system (CNS) metastases or a primary CNS tumor that is associated with progressive neurological symptoms.

13. Clinically symptomatic interstitial lung disease or interstitial pneumonitis including radiation pneumonitis

14. Patients in Groups 1-5 and 7 (Part 2) previously treated with a selective RET inhibitor

1. "A diagnosis of ataxia telangiectasia

2. Prior exposure to an ATR inhibitor

3. Bad reaction to AZD6738

4. Module 1: Contra-indicated for treatment with carboplatin

5. Module 2: Contra-indicated for treatment with olaparib

6. Module 3: Contra-indicated for treatment with MEDI4736"

1. Distant metastasis (clinical stage M1). Nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion. Diagnosis of distant metastasis (clinical M stage; M0 versus M1a, M1b, M1c) and pelvic nodal disease (clinical N stage; N1 versus N0) will be assessed by central radiological review. Participants are considered eligible only if the central radiological review confirms clinical stage M0

2. Prior treatment with antiandrogen

3. History of pelvic radiation for prostate cancer

4. Use of any investigational agent less than or equals to (<=)4 weeks prior to randomization or any therapeutic procedure for prostate cancer at any time

5. Major surgery <=4 weeks prior to randomization

1. Progression/recurrence of breast cancer during or within 3 months of completion of neoadjuvant or adjuvant chemotherapy.

2. Ongoing neuropathy or other chemotherapy or radiation-related toxicities that are moderate (Grade 2) or worse in severity.

3. Known brain metastases, unless previously treated and asymptomatic for 2 months and not progressive in size or number for 2 months.

4. Significant cardiovascular disease.

5. Previously received capecitabine and discontinued due to progression or intolerance; previously received CDX-011 or other MMAE containing agents.

6. Active systemic infection requiring treatment. Infection controlled by oral therapy will not be exclusionary.

7. Chronic use of systemic corticosteroids.

Part 1:

1. Known hypersensitivity to the trial drugs or their excipients or risk of allergic of anaphylactic reaction to drug product according to Investigator judgement (e.g. patient with history of anaphylactic reaction or autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs (NSAIDs), inhaled corticosteroids, or the equivalent of </= 10 mg/day prednisone).
2. Known immunodeficiency virus infection or an active hepatitis B or C virus infection.
3. History of severe hypersensitivity reactions to other mAbs.
4. Immunosuppressive corticosteroid doses (> 10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of trial medication.
5. Current or prior treatment with any systemic anti-cancer therapy either within 28 days or a minimum of 5 half-lives, whichever is shorter before start of treatment.
6. Serious concomitant disease, especially those affecting compliance with trial requirements or which are considered relevant for the evaluation of the endpoints of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastrointestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the investigator would make the patient inappropriate for entry into the trial.
7. Major injuries and/or surgery or bone fracture within 4 weeks of start of treatment, or planned surgical procedures during the trial period.
8. Patients with personal or family history of QT prolongation and/or long QT syndrome, or prolonged QTcF at baseline (> 480 ms).
9. Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 6 months, congestive heart failure > NYHA II).
10. Uncontrolled hypertension defined as: Blood pressure in rested and relaxed condition >= 140 mmHg, systolic or >= 90 mmHg diastolic (with or without medication), measured according to Appendix 10.2.
11. LVEF < 50%
12. History of severe hemorrhagic or thromboembolic event in the past 12 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis).
13. Known inherited predisposition to bleeding or to thrombosis in the opinion of the investigator.
14. Patient with brain metastases that are symptomatic and/or require therapy.
15. Patients who require full-dose anticoagulation (according to local guidelines). No Vitamin K antagonist and other anticoagulation allowed; LMWH allowed only for prevention not for curative treatment.
16. History of pneumonitis within the last 5 years
17. Patients who are under judicial protection and patients who are legally institutionalized.
18. Patients unable or unwilling to comply with protocol
19. Previous enrolment in this trial (Part 1 or Part 2).
20. Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial patient or unlikely to complete the trial.
21. Women who are pregnant, nursing, or who plan to become pregnant in the trial

Part 2:

1. Known hypersensitivity to the trial drugs or their excipients or risk of allergic of anaphylactic reaction to drug product according to Investigator judgement (e.g. patient with history of anaphylactic reaction or autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs (NSAIDs), inhaled corticosteroids, or the equivalent of </= 10 mg/day prednisone).
2. Not more than one CPI based treatment regimen prior to entering study (eg. anti-Programmed Death receptor-1 (PD-1), anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, or anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) antibody) unless combination CPIs approved by the local regulatory agencies; For eg., Melanoma cohort (Cohort E).
3. Known HIV infection
4. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (exception for patients in HCC cohorts; Cohorts F& G).
5. History of severe hypersensitivity reactions to other mAbs.
6. Immunosuppressive corticosteroid doses (> 10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of trial medication except for control of cerebral edema in case of recurrent glioblastoma (cohort D).
7. Current or prior treatment with any systemic anti-cancer therapy (including radiotherapy) either within 28 days or a minimum of 5 half-lives, whichever is shorter before start of treatment
8. Serious concomitant disease, especially those affecting compliance with trial requirements or which are considered relevant for the evaluation of the endpoints of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastrointestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the investigator would make the patient inappropriate for entry into the trial.
9. Major injuries and/or surgery or bone fracture within 4 weeks of start of treatment, or planned surgical procedures during the trial period.
10. Patients with personal or family history of QT prolongation and/or long QT syndrome, or prolonged QTcF at baseline (> 480 ms).
11. Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 6 months, congestive heart failure > NYHA II).
12. Uncontrolled hypertension defined as: Blood pressure in rested and relaxed condition >= 140 mmHg, systolic or >= 90 mmHg diastolic (with or without medication), measured according to Appendix 10.2.
13. LVEF < 50%
14. History of severe hemorrhagic or thromboembolic event in the past 12 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis).
15. Known inherited predisposition to bleeding or to thrombosis in the opinion of the investigator.
16. Patient with brain metastases that are symptomatic and/or require therapy.
17. Patients who require full-dose anticoagulation (according to local guidelines).
18. No Vitamin K antagonist and other anticoagulation allowed; LMWH allowed only for prevention not for curative treatment.
19. History of pneumonitis (non-infectious) within the last 5 years
20. Patients who are under judicial protection and patients who are legally institutionalized.
21. Patients unable or unwilling to comply with protocol
22. Previous enrolment in this trial.
23. Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial patient or unlikely to complete the trial.
24. Women who are pregnant, nursing, or who plan to become pregnant in the trial
25. UncontrolledSymptomatic pleural effusion, pericardial effusion, or ascites
26. Prior treatment with any antiangiogenic treatment (e.g. bevacizumab, cediranib, aflibercept, vandetanib, XL-184, sunitinib, etc) except for sorafenib and lenvatinib in 2nd line HCC cohort (Cohort F)
27. Has received a live vaccine within 30 days prior to the first dose of study drug
28. Patients with known active second malignancy other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer, and ductal or lobular carcinoma in situ of the breast. Patients are not considered to have a currently active malignancy if they have completed anticancer therapy and have been disease free for greater than 2 years prior to screening
29. Further exclusion criteria apply

1. Patient pregnant, or breast-feeding.

2. Uveal melanoma.

3. Active and/or symptomatic intra cranial metastasis (including melanomatous meningitis).

4. Previous treatment with B-RAF or MEK inhibitors within 12 weeks prior start of treatment.

5. Hypersensitivity to the drugs of the study.

6. Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

7. Clinically significant cardiac dysfunction including congenital, familial, and genetic cardiac disorders, current instable angina, current symptomatic congestive heart failure of NYHA class 2 and higher, current uncontrolled hypertension ≥ grade 3; Left Ventricular Ejection Fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower.

8. Patient with active malignancy other than melanoma or a history of previous within the past 3 years; except for patients with resected Basal cell carcinoma or resected Spindle cell carcinoma, resected carcinoma in situ of the cervix and resected carcinoma in situ of the breast.

9. Active, known or suspected autoimmune disease including but not restricted to multiple sclerosis, optical nevritis and demyelinating neuropathy. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.

10. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus (ribonucleic acid or HCV antibody) indicating acute or chronic infection.

11. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).

12. Vaccination with any live attenuated conventional vaccine within the 3 months preceding the start of study treatment.

13. Any current severe or uncontrolled disease, including, but not limited to ongoing or active infection.

14. Patient included in another study with an experimental molecule and/or procedure.

15. Unwillingness or inability to provide written informed consent.

16. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the compliance of treatment and the study protocol.

17. Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

1. Other histology than squamous cell carcinoma

2. pT3 or pT4

3. pT2>3cm and R1 with concurrent chemoradiotherapy decided in multidisciplinary tumor board

4. Lymphovascular invasion justifying neck irradiation

5. Neck irradiation decided in multidisciplinary tumor board

6. Lack of at least one of the following elements :

   pre-operative medical imaging (CT scan or MRI)

   endoscopy report

   surgery report

   pathological report

7. Prior radiotherapy to the head and neck area

8. Distant metastasis

9. Pregnant or nursing (lactating) woman

10. women or men of childbearing age not taking adequate contraceptive measure

11. participation in another investigational study within 4 weeks prior to inclusion

12. History of other malignancy within 5 years prior enrollment except for basal cell carcinoma of the skin or carcinoma in situ of the cervix

13. Persons deprived of their liberty, under guardianship or curatorship, or unable to follow the trial for geographical, social or psychological reasons

1. Subjects who received prior treatment with the following therapies (calculation is based on date of last therapy to date of first dose of study treatment): a. Docetaxel at any time. b. Any of the investigational agents being tested in the current study, including experimental ICOS agonist. c. Systemic approved or investigational anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug is administered. d. Prior radiation therapy: permissible if at least one non-irradiated measurable lesion is available for assessment per RECIST version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least 2 weeks before start of study drug for radiation of any intended use is required.

2. Received >=3 prior lines of therapy for NSCLC, including subjects with BRAF molecular alternations.

3. Invasive malignancy or history of invasive malignancy other than disease under study within the last 2 years.

4. Central nervous system (CNS) metastases, with the following exception: Subjects with asymptomatic CNS metastases who are clinically stable and have no requirement for steroids for at least 14 days prior to first dose of study treatment.

5. Major surgery <= 28 days of first dose of study treatment.

6. Autoimmune disease (current or history) or syndrome that required systemic treatment within the past 2 years. Replacement therapies which include physiological doses of corticosteroids for treatment of endocrinopathies (for example, adrenal insufficiency) are not considered systemic treatments.

7. Receiving systemic steroids (>=10 milligram [mg] oral prednisone or equivalent) or other immunosuppressive agents within 7 days prior to first dose of study treatment.

8. Prior allogeneic/autologous bone marrow or solid organ transplantation.

9. Receipt of any live vaccine within 30 days prior to first dose of study treatment.

10. Toxicity from previous anticancer treatment that includes: a. >= Grade 3 toxicity considered related to prior immunotherapy and that led to treatment discontinuation. b. Toxicity related to prior treatment that has not resolved to <= Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be <= Grade 2).

11. History (current and past) of idiopathic pulmonary fibrosis, pneumonitis (for past-pneumonitis exclusion only if steroids were required for treatment), interstitial lung disease, or organizing pneumonia.

12. Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions.

13. Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess.

14. History or evidence of cardiac abnormalities within the 6 months prior to enrollment.

15. Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypo-albuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.

16. Active infection requiring systemic therapy.

17. Subjects with known human immunodeficiency virus infection, or positive test for hepatitis B active infection (presence of hepatitis B surface antigen), or hepatitis C active infection.

18. Subjects with history of severe hypersensitivity to monoclonal antibodies or hypersensitivity to ingredients used in the formulation of docetaxel.

19. Subjects requiring ongoing therapy with a medication that is a strong inhibitor or inducer of the cytochrome 3A4 (CYP3A4) enzymes.

20. Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other condition that could interfere with participant's safety, obtaining informed consent, or compliance to the study procedures in the opinion of the investigator.

21. Pregnant or lactating female subjects.

22. Subject is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment

1. Patients with symptomatic central nervous system (CNS) metastases or other tumor location (such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture, etc.) necessitating an urgent therapeutic intervention, palliative care, surgery or radiation therapy

2. Congestive heart failure (New York Heart Association Class III or IV) or unstable angina pectoris. Previous history of myocardial infarction within 1 year prior to study entry, uncontrolled hypertension or uncontrolled arrhythmias

3. Pulmonary disease (e.g. COPD, asthma, etc) that is not controlled (moderate to severe symptoms) with current medication

4. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therap

1. ECOG PS >2;

2. Known hypersensitivity to immunotherapy;

3. Small-cell lung cancer, bronchioloalveolar cancer, neuroendocrine cancer;

4. Tumor harbors EGFR-sensitizing (activating) mutations or ALK translocations or ROS1 fusions and that justify treatment with targeted therapy ;

5. Chemotherapy, hormonotherapy, immunotherapy or tyrosine-kinase inhibitors within the past 4 weeks prior to treatment with the trial drug;

6. Radiotherapy (except bone or brain) within the past 3 months prior to baseline imaging;

7. Medical contraindication to oral vinorelbine;

8. Persistence of clinical adverse events related to prior treatment;

9. Active brain metastases (e.g. stable for <4 weeks, no adequate previous radiotherapy, symptomatic, requiring anticonvulsants; dexamethasone will be allowed if administered at a stable dose <10 mg/day for at least 1 month before randomization);

10. Concurrent radiotherapy, except for palliative bone irradiation.

11. Other concurrent severe illnesses (congestive heart failure, unstable angina, significant arrhythmia or myocardial infarction <12 months before study entry);

12. Active or prior documented autoimmune or inflammatory disorders;

13. Active B hepatitis, HIV infection …;

14. Psychiatric or neurological disorders preventing the patient from understanding the nature of the trial;

15. Grade-3 peripheral neuropathy;

16. Uncontrolled infection;

17. Interstitial lung disease or pneumonitis requiring steroid management;

18. Corticosteroid therapy exceeding 10 mg/day;

19. Other severe organic disorders not allowing inclusion in the trial;

20. Malabsorption syndrome;

21. Pregnancy or breast-feeding;

22. Follow-up not possible; and incarcerated or institutionalized patients.